Impact of topical corticosteroid pretreatment on susceptibility of the injured murine cornea to Pseudomonas aeruginosa colonization and infection.
Administration, Ophthalmic
Animals
Cornea
/ drug effects
Corneal Injuries
/ diagnosis
Corneal Ulcer
/ diagnosis
Disease Models, Animal
Disease Susceptibility
Epithelium, Corneal
/ injuries
Eye Infections, Bacterial
/ diagnosis
Female
Fluorescein
/ metabolism
Fluorescent Dyes
/ metabolism
Glucocorticoids
/ therapeutic use
Mice
Mice, Inbred C57BL
Prednisolone
/ analogs & derivatives
Premedication
Pseudomonas Infections
/ diagnosis
Pseudomonas aeruginosa
/ isolation & purification
Retrospective Studies
Wound Healing
Bacterial colonization
Corticosteroid pretreatment
Epithelial healing
Microbial keratitis
Murine cornea
Pseudomonas aeruginosa
Superficial injury
Journal
Experimental eye research
ISSN: 1096-0007
Titre abrégé: Exp Eye Res
Pays: England
ID NLM: 0370707
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
28
06
2018
revised:
04
09
2018
accepted:
17
10
2018
pubmed:
22
10
2018
medline:
16
4
2019
entrez:
22
10
2018
Statut:
ppublish
Résumé
Research with animal models of Pseudomonas aeruginosa keratitis has shown that use of a topical corticosteroid alone against an established infection can significantly increase the number of colonizing bacteria or worsen clinical disease. Moreover, retrospective analysis has suggested that corticosteroid use in humans is associated with an increased risk of keratitis in eyes with pre-existing disease. Thus, while corticosteroids are often used to reduce ocular inflammation in the absence of infection, the risk of opportunistic infection remains a concern. However, the effect of corticosteroids on the intrinsic barrier function of uninfected corneas is unknown. Here, we tested if short-term topical corticosteroid treatment of an uninfected murine cornea would increase susceptibility to P. aeruginosa colonization or infection after epithelial injury. Topical prednisolone acetate (1%) was administered to one eye of C57BL/6 mice three times a day for 3 days; control eyes were treated with sterile PBS. Prior to inoculation with a cytotoxic P. aeruginosa corneal isolate strain 6206, corneas were subject to superficial-injury by tissue paper blotting, or scratch-injured followed by 12 h of healing. Previously we have shown that blotting renders mouse corneas susceptible to P. aeruginosa adhesion, but not infection, while 12 h healing reduces susceptibility to infection after scratching. Corneas were evaluated at 48 h for bacterial colonization and microbial keratitis (MK). To monitor impact on wound healing, corneal integrity was examined by fluorescein staining immediately after scarification and after 12 h healing. For both the tissue paper blotting and scratch-injury models, there was no significant difference in P. aeruginosa colonization at 48 h between corticosteroid-pretreated eyes and controls. With the blotting model, one case of MK was observed in a control (PBS-pretreated) cornea; none in corticosteroid-pretreated corneas. With the 12 h healing model, MK occurred in 6 of 17 corticosteroid-pretreated eyes versus 2 of 17 controls, a difference not statistically significant. Corticosteroid-pretreated eyes showed greater fluorescein staining 12 h after scarification injury, but this did not coincide with increased colonization or MK. Together, these data show that short-term topical corticosteroid therapy on an uninfected murine cornea does not necessarily enhance its susceptibility to P. aeruginosa colonization or infection after injury, even when it induces fluorescein staining.
Identifiants
pubmed: 30343040
pii: S0014-4835(18)30466-4
doi: 10.1016/j.exer.2018.10.010
pmc: PMC6360113
mid: NIHMS1510378
pii:
doi:
Substances chimiques
Fluorescent Dyes
0
Glucocorticoids
0
prednisolone acetate
8B2807733D
Prednisolone
9PHQ9Y1OLM
Fluorescein
TPY09G7XIR
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-7Subventions
Organisme : NEI NIH HHS
ID : K12 EY017269
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY003176
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY011221
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY023000
Pays : United States
Informations de copyright
Copyright © 2018. Published by Elsevier Ltd.
Références
Acta Ophthalmol (Copenh). 1953;31(1):75-89
pubmed: 13039983
PLoS One. 2011;6(8):e24008
pubmed: 21901151
Br J Ophthalmol. 1982 Nov;66(11):705-8
pubmed: 6896993
Br J Ophthalmol. 2016 Dec;100(12):1714-1718
pubmed: 27030278
Infect Immun. 2009 Jun;77(6):2392-8
pubmed: 19349424
Arch Ophthalmol. 1985 May;103(5):718-22
pubmed: 3843063
JAMA Ophthalmol. 2013 Feb;131(2):147-53
pubmed: 23411878
Invest Ophthalmol Vis Sci. 2011 Mar 14;52(3):1368-77
pubmed: 21051692
Medicine (Baltimore). 2017 Feb;96(5):e5864
pubmed: 28151861
J Cataract Refract Surg. 2000 Jun;26(6):893-7
pubmed: 10889437
Sci Rep. 2011;1:8
pubmed: 22355527
Graefes Arch Clin Exp Ophthalmol. 2005 Dec;243(12):1200-5
pubmed: 16235062
BioDrugs. 1998 Oct;10(4):329-39
pubmed: 18020605
Curr Eye Res. 2003 Nov;27(5):289-99
pubmed: 14562165
Infect Immun. 2005 Apr;73(4):2147-56
pubmed: 15784557
Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5220-7
pubmed: 14638720
Br J Ophthalmol. 2016 Jun;100(6):731-5
pubmed: 26743622
Invest Ophthalmol Vis Sci. 1977 Jun;16(6):553-6
pubmed: 405346
Exp Eye Res. 2011 Mar;92(3):209-20
pubmed: 21195713
Infect Immun. 2015 Apr;83(4):1629-40
pubmed: 25667266
Proc Soc Exp Biol Med. 1983 Apr;172(4):488-91
pubmed: 6844357
FASEB J. 2017 Jun;31(6):2393-2404
pubmed: 28223334
J Cell Biol. 2018 Feb 5;217(2):731-744
pubmed: 29191848
Invest Ophthalmol Vis Sci. 2003 Sep;44(9):3892-8
pubmed: 12939306
Invest Ophthalmol Vis Sci. 1997 Apr;38(5):910-8
pubmed: 9112987
PLoS One. 2017 Aug 10;12(8):e0182153
pubmed: 28796783
Ophthalmology. 1997 May;104(5):816-22
pubmed: 9160028
Cochrane Database Syst Rev. 2017 Feb 07;2:CD011965
pubmed: 28170093
PLoS One. 2013;8(2):e57850
pubmed: 23469087
Infect Immun. 2006 Jul;74(7):3880-9
pubmed: 16790760
Infect Immun. 2003 Sep;71(9):5389-93
pubmed: 12933890
Infect Immun. 1994 May;62(5):1799-804
pubmed: 8168942
Eye (Lond). 2016 Mar;30(3):447-55
pubmed: 26634710
Am J Ophthalmol. 2014 Feb;157(2):327-333.e3
pubmed: 24315294
Exp Eye Res. 2016 Nov;152:10-33
pubmed: 27600171
Arch Ophthalmol. 1990 Jul;108(7):1001-5
pubmed: 2369336
Infect Immun. 2011 Feb;79(2):595-605
pubmed: 21115716
Exp Eye Res. 2013 Dec;117:53-61
pubmed: 23880529
Can J Ophthalmol. 2011 Feb;46(1):40-5
pubmed: 21283156
Am J Ophthalmol. 2013 Jun;155(6):961-970.e2
pubmed: 23601656
J Clin Invest. 2012 Oct;122(10):3665-77
pubmed: 23006328
Sci Rep. 2017 Oct 23;7(1):13829
pubmed: 29062042
Prog Retin Eye Res. 2015 Nov;49:17-45
pubmed: 26197361